Table 3.
Peptide reactivity, immune response rate and clinical response.
| Peptide reactivity (number of tested peptides) | ||||
|---|---|---|---|---|
|
|
||||
| Patient ID | Prevaccination | Postvaccination | TTP (wks) | Survival (wks) |
| MR-1 | a10/15b | 7/13 (2)c | 7 | 31 |
| MR-2 | 12/16 | 15/17 (11) | 23 | 79 |
| MR-4 | 13/14 | 15/17 (7) | 35 | 68 |
| MR-5d | 3/14 | 15/15 (11) | 7 | 76 |
| MR-6d | 8/16 | 3/17 (1) | 6 | 18 |
| MR-7d | 2/16 | 5/15 (5) | 28 | 84 |
| MR-9 | 3/18 | 4/17 (1) | 39 | 79 |
| MR-10 | 16/19 | 13/19 (0) | 23 | 55 |
| MR-11 | 7/17 | 7/15 (3) | SD (7)e | 17 |
| MR-13 | 13/18 | 13/18 (4) | 33 | 104 (alive) |
| MR-14 | 9/19 | 17/19 (9) | 35 | 107 |
| MR-15 | 6/19 | 15/19 (8) | SD (131)e | 151 (alive) |
| Immune response rate (%) | 100f | 100 (75)f | ||
| Clinical response (wks) | 25.5g | 77.5g | ||
TTP, time to progression; SD, stable disease.
a
Numbers of peptides to which reactivity was observed (>10 spots above background).
b
Numbers of peptides tested (survivin, cyclin D1, adipophilin, c-MET, vimentin, PRUNE2, VEGF, NY-ESO, MMP7, TYMS, IGF-BP3, RGS-5, CA IX, CP, TIF-1, ORMDL3, CLIC1, ELAC2 and PIG-10).
c
Numbers of peptides (in bold) to which a greater-than-two-fold increase after versus before vaccination was detectable.
d
Short protocol of vaccination starting with the middle dose of 107 vaccine cells.
e
SD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
f
Patients reacting to more than one peptide in %.
g
Median PD and median survival in weeks.